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Advisor: Dr. Rose Goodchild 
 
Biochemistry and Cellular and Molecular Biology, The University of Tennessee, Knoxville
Multiple sclerosis (MS) is a neurodegenerative disorder caused by a prolonged immune-
mediated inflammatory response that targets myelin. Nearly all of the drugs approved for the 
treatment of MS are general immunosuppressants or only function in symptom management. 
The oral medication fingolimod, however, is reported to have direct therapeutic effects on 
cells of the central nervous system in addition to immunomodulatory functions. Fingolimod 
is known to interact with sphingosine-1-phosphate (S1P) receptors, and the most widely-
accepted theory for its mechanism of action is functional antagonism of the receptor. This 
review examines significant neuromodulatory effects achieved by functional antagonism of 
the receptors S1P1 and S1P3 on astrocytes and speculates on the potential role of S1P 
receptors in the pathogenesis of MS.Introduction
INTRODUCTION 
0XOWLSOH6FOHURVLV06LVDQLPPXQHPHGLDWHGLQÁDPPDWRU\QHXURORJLFDOGLVRUGHUWKDWDIIHFWV
approximately 1 in every 1000 people.1 The disease is characterized by recurring damage to the 
myelin sheath that surrounds the axons of nerve cells.  The myelin sheath is composed of layers 
RIFHOOXODUPHPEUDQHJHQHUDWHGE\ VSHFLDOL]HGP\HOLQIRUPLQJFHOOV²6FKZDQQFHOOV LQ WKH
peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS). 
Multiple layers of this membrane envelope axons, forming a thick, protective covering. The 
P\HOLQVKHDWKVHUYHVDVDQ LQVXODWRU WKDW LQFUHDVHV WKHVSHHGDQGHIÀFLHQF\RI LRQPHGLDWHG
nerve impulses.5 :KHQ LW LV GDPDJHGE\ WKH LQÁDPPDWRU\ IDFWRUV DVVRFLDWHGZLWK06 WKH
ability of nerve cells to conduct impulses is impaired.
06H[KLELWVDÁXFWXDWLQJSDWWHUQRIGLVHDVHVHYHULW\LQZKLFKHPLVVLRQSHULRGVZLWKUHGXFHG
symptoms alternate with periods of heightened disease activity.  During relapses, regions 
of active demyelination develop in the brain and central nervous system (CNS), forming the 
characteristic MS lesions. Over time, the duration and the severity of attacks increase, and 
the disease transitions from the relapsing-remitting (RR) stage to the progressive stage in which 
continual axonal damage occurs.
While the clinical manifestations of MS have been documented since the nineteenth century, 
the basic molecular pathology of the disease continues to be debated.   Multiple sclerosis 
is a complex disorder that involves interactions among several different body systems and 
numerous molecular components. Additionally, it is a heterogeneous disease that appears to 
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have different pathological characteristics in distinct subsets of patients. While much research 
has been conducted on physiological elements that contribute to the MS disease mechanism, 
many details still remain unclear.
No cure has been developed for MS, but a variety of treatments have been approved by the 
FDA. 7KHGUXJNQRZQDVÀQJROLPRG*LOHQ\DGHYHORSHGE\1RYDUWLVDQGDSSURYHGIRU
WKH WUHDWPHQW RIPXOWLSOH VFOHURVLV LQ 6HSWHPEHU  KDV EHHQ WKH VXEMHFW RI SDUWLFXODUO\
intensive study.87KHUHLVHYLGHQFHWKDWÀQJROLPRG·VPHFKDQLVPRIDFWLRQPD\LQFOXGHGLUHFW
CNS neuromodulatory effects, presenting the possibility of a pharmacological MS research 
approach.9 8 Examining the molecular interactions and responses that contribute to this drug’s 
function has the potential to provide valuable insight into the disease mechanisms associated 
with multiple sclerosis.
Molecular Pathology of MS
The prevailing theory states that multiple sclerosis results from an autoimmune reaction that 
FDXVHVSHULYDVFXODU LQÁDPPDWLRQDQGGHP\HOLQDWLRQDVZHOO DVRWKHU UHODWHG IRUPVRIQHUYH
damage.6, 107KH LQÁDPPDWRU\UHVSRQVHEHJLQVZKHQPDMRUKLVWRFRPSDWLELOLW\FRPSOH[FODVV
II (MHCII) molecules on the surface of macrophages and B-cells present a myelin antigen 
WR&'7FHOOVDQGUHQGHUWKHPP\HOLQUHDFWLYH The exact nature of the myelin antigen 
is unknown, but studies have found that immune cells can be triggered to produce antibodies 
targeting different component proteins of myelin including myelin basic protein, myelin 
proteolipid protein, and myelin/oligodendrocyte glycoprotein. 
0\HOLQUHDFWLYH&'7FHOOVGLIIHUHQWLDWHLQWRDSDWKRJHQLF7FHOOVXEW\SHWKDWSURGXFHVKLJK
OHYHOVRILQÁDPPDWRU\F\WRNLQHVDQGLQKLELWVWKHIXQFWLRQLQJRIUHJXODWRU\7FHOOV3HUKDSV
because of this altered T-cell phenotype or as a result of an existing genetic mutation, MS is 
FKDUDFWHUL]HGE\GHFUHDVHGIXQFWLRQRIUHJXODWRU\7FHOOVRIWKHW\SH&'&')R[3 
These normally suppress T-cell immune reactions after an infection has been cleared, and they 
DUHDOVRUHVSRQVLEOHIRULQKLELWLQJDXWRUHDFWLYH7FHOOVWKDWDUHQRWWROHUDQWRI´VHOIµDQWLJHQV 
2QHVWXG\KDV IRXQG WKDW06SDWLHQWVKDYHDQDEQRUPDOYHUVLRQRI WKH)R[3 WUDQVFULSWLRQ
factor that normally mediates these regulatory T-cell functions. It has been demonstrated that 
WKHDGGLWLRQRIIXQFWLRQDO&'&'7FHOOVFDQSUHYHQWWKHGHYHORSPHQWRIH[SHULPHQWDO
autoimmune encephalomyelitis (EAE), a disease model used to study multiple sclerosis in 
ODERUDWRU\DQLPDOVDQGWKDWWKHUHPRYDORIWKHVHUHJXODWRU\7FHOOVLVVXIÀFLHQWWRFDXVHFHUWDLQ
other autoimmune disorders. Thus, the reduced function of these cells is a key factor in the 
pathology of MS, allowing for the proliferation of activated T-cells that lack immunological 
tolerance.
7KHVH UHDFWLYH7FHOOV VWLPXODWH%FHOOV WRSURGXFHP\HOLQVSHFLÀFDQWLERGLHV7KH\ UHFUXLW
F\WRWR[LF &' 7FHOOV DQG SURGXFH DGKHVLRQ PROHFXOHV WR IDFLOLWDWH LQWHUDFWLRQ ZLWK WKH
cerebral endothelial cells (CECs) that are a key component of the blood-brain barrier (BBB).6 
  Activated T-cells, B cells, and macrophages then cross the BBB by integrin-mediated 
transendothelial migration.8 11 In the CNS, T-cells destroy the myelin layer, and invading 
macrophages as well as the resident immunoreactive cells in the CNS known as microglia 
release signaling molecules that activate Fas cell death signal receptors on oligodendrocytes.8 
The signaling cascades induce lysis, further reducing the myelin sheath and triggering the 
release of additional myelin antigens. The continued presentation of these antigens on CECs, 
PLFURJOLD DQG DVWURF\WHV UHVXOWV LQ WKH SHUVLVWHQW UHFUXLWPHQW RI LQÁDPPDWRU\ DJHQWV$V
the disease progresses, regions of demyelination accumulate around cerebral blood vessels, 
forming lesions or plaques.6 It has been suggested that the locations of these plaques in the CNS 
determine the symptoms that individual patients experience, but this correlation is not precise.
15 6
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Immunoreactive cells in the CNS can also contribute to other aspects of MS-related neuropathy.
16 Macrophages produce oxidative free radicals, proteases, and toxic compounds that cause tissue 
damage.  Microglia and astrocytes proliferate at the sites of CNS damage, causing a condition 
known as gliosis. Reactive astrogliosis in particular is a common feature in the pathology of 
MS.17 10 16:KLOHWKLVELRORJLFDOUHVSRQVHFDQKDYHDEHQHÀFLDOIXQFWLRQLQSUHYHQWLQJWKHVSUHDG
RI LQÁDPPDWRU\ DJHQWV LQWRKHDOWK\&16 WLVVXH WKH DVWURJOLDO VFDUULQJ WKDW UHVXOWV SUHYHQWV
axonal regeneration following nerve damage.16-17 Additionally, certain signaling pathways 
VWLPXODWH UHDFWLYH DVWURF\WHV WR SURGXFH SURLQÁDPPDWRU\ F\WRNLQHV QHXURWR[LF UHDFWLYH
R[\JHQ VSHFLHV DQG F\WRWR[LF VLJQDOLQJPROHFXOHV WKDW DJJUDYDWH WKH LQÁDPPDWRU\ UHDFWLRQ
and contribute to the breakdown of the BBB.16 18 
As with other autoimmune disorders, the initial trigger that stimulates the immune system to 
UHDFWWRD´VHOIµDQWLJHQDQGFDXVH06KDVQRWEHHQHOXFLGDWHG6HYHUDOFDXVDWLYHIDFWRUVIRU
MS have been proposed, however, on the basis of trends in patient demographics. Research 
KDV FRQÀUPHG D JHQHWLF FRPSRQHQW DVVRFLDWHG ZLWK PXOWLSOH VFOHURVLV EXW JHQHV DUH RQO\
 SUHGLFWLYH RI GLVHDVH GHYHORSPHQW 7KH JHQHWLF FRPSRQHQWPRVW OLNHO\ UHÁHFWV D
SUHGLVSRVLWLRQWRH[DJJHUDWHGRULQDSSURSULDWHLQÁDPPDWRU\UHVSRQVHGXHWRDSRO\PRUSKLVP
LQWKHSURPRWHUUHJLRQRIDQXQLGHQWLÀHGLPPXQHV\VWHPUHDFWLYLW\JHQHAdditional genetic 
factors might pertain to an individual’s natural hormone levels, which can affect the abundance 
RISURRUDQWLLQÁDPPDWRU\PROHFXOHVLQWKHERG\19
The molecular mimicry hypothesis suggests that T-cells may in fact be activated by an external 
antigen and then induced to attack myelin because its component proteins are chemically similar 
to the original antigen. A related hypothesis suggests that a viral infection is responsible for 
activating T-cells and directing them to attack myelin. One of the most convincing correlations 
between virus infection and MS is the incidence of the Epstein-Barr virus (EBV). The connection 
EHWZHHQ(39DQG06KDVORQJEHHQUHSRUWHGDQGUHFHQWVWXGLHVKDYHGHPRQVWUDWHGVLJQLÀFDQW
increases in the risk of MS after infection with EPV, and correspondingly a very low incidence 
of MS among individuals that have not contracted EPV. Some component of the viral infection 
or the immune response to it seem to prime the body for later development of MS. 
Environmental factors have also been implicated in the onset of multiple sclerosis.  The 
GLVHDVHH[KLELWVDFOHDUJHRJUDSKLFDOGLVWULEXWLRQLWLVPRVWSUHYDOHQWLQLQGLYLGXDOVWKDWVSHQG
the early years of their lives in the northernmost and southernmost regions of the world, and 
LW LV VLJQLÀFDQWO\ OHVV FRPPRQ LQ HTXDWRULDO UHJLRQV 2QH H[SODQDWLRQ IRU WKH JHRJUDSKLFDO
correlation involves the effect of sunlight on vitamin D levels in the human body. UV radiation 




triggered disorders such as MS.  
In recent years, a new causative theory of MS has evoked widespread interest and criticism. The 
theory originated with a controversial study that reported the presence of chronic cerebrospinal 
YHQRXV LQVXIÀFLHQF\ &&69, LQ D VLJQLÀFDQW SHUFHQWDJH RI06 SDWLHQWV7KLV FRQGLWLRQ LV
characterized by a narrowing of the veins that drain blood from the brain and spinal cord, 
resulting in circulation problems and shunting of blood to other vessels.This was publicized 
DVDFDXVDWLYHIDFWRURIPXOWLSOHVFOHURVLVDQGWKHUDSHXWLFVXUJHULHVWRLQFUHDVHEORRGÁRZLQ
the CNS were prescribed. The fact that increased perivascular iron levels have been observed 
in the CNS of a number of MS patients, an effect often associated with restricted circulation, 
has lent support to the CCSVI hypothesis. Subsequent research on the subject has produced 
YDULDEOHÀQGLQJVKRZHYHUDQGWKHPHWKRGRORJ\HPSOR\HGLQ WKHRULJLQDO&&69,VWXG\KDV
been severely criticized. Recent meta-analysis of applicable studies on CCSVI suggests that it 
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Integration of these proposed causative factors suggests that the development of MS is likely the 
result of an external trigger acting on a genetically and physiologically predisposed individual.
Molecular Mechanisms of FTY720 (Fingolimod) Efficacy
Because there is no known cure for MS, the goals of pharmaceutical treatment are primarily 
to slow the progression of the disease and to improve patients’ quality of life. Consistent with 
this philosophy, nearly all of the drugs approved for the treatment of multiple sclerosis are 
JHQHUDOLPPXQRVXSSUHVVDQWVDQWLLQÁDPPDWRU\VWHURLGVRUGUXJVWKDWIXQFWLRQRQO\LQWUHDWLQJ
common symptoms such as fatigue. There are numerous disadvantages associated with this 
limited therapeutic approach. In addition to potentially serious side effects, immunomodulatory 
GUXJVKDYH OLPLWHGHIÀFDF\GXULQJSURJUHVVLYHVWDJH06ZKHQUHDFWLYH LPPXQHFHOOVDUHQR
longer the primary cause of neurodegeneration. Furthermore, general immunosuppressive 
drugs are not the ideal treatment for a heterogeneous, multifocal disease like multiple sclerosis.6
7KHSURGUXJ)7<DSSURYHGE\WKH)'$LQ6HSWHPEHUDQGPDUNHWHGDVÀQJROLPRG
RU*LOHQ\DPD\EHWKHÀUVWGUXJWRDGGUHVVWKLVGHÀFLWLQWKHSKDUPDFHXWLFDOWUHDWPHQWRI068 
&OLQLFDO WULDOV KDYH GHPRQVWUDWHG LWV HIÀFDF\ LQ UHGXFLQJ WKH IUHTXHQF\ DQG VHYHULW\ RI06
relapses, decreasing the size and number of active MS lesions, and preventing brain volume 
loss, suggesting a role in tissue preservation and potentially repair.7 8 Patients treated with 
ÀQJROLPRGDOVRUHWDLQIXQFWLRQLQJQDwYH7FHOOVPLQLPL]LQJWKHULVNRIRSSRUWXQLVWLFLQIHFWLRQ
)XUWKHUPRUHWKLVLVWKHÀUVW06PHGLFDWLRQWKDWFDQEHWDNHQRUDOO\PDNLQJLWDPRUHGHVLUDEOH
WUHDWPHQWRSWLRQ IRUSDWLHQWVDQGVWXGLHVKDYHGHPRQVWUDWHG WKDWÀQJROLPRG LV LQ IDFWPRUH
effective than immunomodulatory interferons in treating multiple sclerosis.
While not fully characterized, much research has been conducted regarding the mechanism 
RI DFWLRQRIÀQJROLPRG)7< LV SKRVSKRU\ODWHG LQYLYRE\ VSKLQJRVLQHNLQDVH 6.
DQGWKHSKRVSKRU\ODWHGDQDORJXHDFWVDVDQRQVHOHFWLYHOLJDQGRIIRXURIWKHÀYHVSKLQJRVLQH
1-phosphate (S1P) G-protein coupled receptors.  Until recently, the majority of research 
KDV IRFXVHG RQ WKH LQWHUDFWLRQV RI )7<3 ZLWK VSKLQJRVLQHSKRVSKDWH UHFHSWRU 
63)7<ZDVRULJLQDOO\WKRXJKWWRIXQFWLRQSXUHO\DVDQ63DJRQLVW Studies had 
GHPRQVWUDWHG WKDW )7<3 ERXQG FRPSHWLWLYHO\ DW WKH OLJDQG ELQGLQJ VLWH DFWLYDWHG WKH
signaling pathway, and triggered endocytosis of the activated receptor. More recent research 
VXJJHVWV WKDW)7<3RSHUDWHV LQVWHDG DV D IXQFWLRQDO DQWDJRQLVW ,QLWLDOO\)7<3
activates the S1P1 receptor and triggers its endocytosis. Following internalization, however, 
the drug maintains the receptor in an active conformation, allowing agonist effects to persist 
IRU DW OHDVW  KRXUV )7<3 ELQGLQJ FDXVHV DQ DOWHUDWLRQ LQ SKRVSKRU\ODWLRQ SDWWHUQV
of the internalized receptor as compared to the natural ligand binding, and this differential 
PRGLÀFDWLRQSUHYHQWVWKHUHFHSWRUIURPEHLQJUHF\FOHGWRWKHSODVPDPHPEUDQHDVLWQRUPDOO\
would.8 Instead, the receptor is degraded, preventing subsequent activation of the signaling 
pathway by the natural ligand S1P.9 8
Immunomodulatory Function
:KHQ)7<ZDVLQLWLDOO\GHYHORSHGLWZDVWKRXJKWWRIXQFWLRQLPPXQRORJLFDOO\E\LQKLELWLQJ
O\PSKRF\WHWUDIÀFNLQJ9 5 8 77FHOOV%FHOOVDQGQDWXUDONLOOHU1.FHOOVQRUPDOO\PLJUDWHIURP
lymphoid organs in response to the concentration gradient of the signaling molecule S1P. If 
lymphocytes are activated by an antigen, they are initially retained in the lymphoid organs 
where they proliferate and differentiate in preparation for the attack on the antigen source. 
Subsequent upregulation of S1P1 on lymphocytes allows S1P to bind the receptor. Activation of 
the associated signaling pathway triggers lymphocyte migration from the lymphoid organs to 
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the source of the antigen.8
Functional antagonism of lymphocytic S1P1 UHFHSWRUV E\ )7<3 LQKLELWV WKH F\FOLF
upregulation of S1P1 and, as a result, diminishes the ability of the receptor to interact with the 
natural ligand. In multiple sclerosis patients, this prevents egress of myelin antigen-activated 
O\PSKRF\WHV WKDWZRXOGRWKHUZLVHEH LQYROYHG LQ WKH LQÁDPPDWRU\ DXWRLPPXQH UHVSRQVH
8 This molecular mechanism has received extensive experimental validation. Fingolimod has 
EHHQVKRZQWRVLJQLÀFDQWO\UHGXFHEORRGO\PSKRF\WHFRXQWVDQGWKHO\PSKRSHQLDLVUHYHUVHG
upon discontinuation of therapy. Fingolimod’s lymphocyte sequestration capacities do not 






of research has begun to question whether this is the drug’s primary mechanism of action. 
Studies have demonstrated that blood lymphocyte counts are not consistently dose-dependent 
DQGGRQRWFRUUHODWHZHOOZLWKWKHFOLQLFDOHIÀFDF\RIWKHGUXJ&RQÁLFWLQJGDWDKDYHEHHQ
UHSRUWHG RQ WKH SRWHQF\ RI ÀQJROLPRG DV DQ LPPXQRVXSSUHVVDQW  )XUWKHUPRUH )7<
UHDGLO\FURVVHVWKH%%%DQGFRQFHQWUDWHVLQWKHEUDLQDQGVSHFLÀFDOO\ORFDOL]HVWRZKLWHPDWWHU
containing myelin. In fact, both the drug and its phosphorylated analog are present in 
VLJQLÀFDQWO\ KLJKHU TXDQWLWLHV LQ WKH EUDLQ WKDQ LQ WKH EORRG RU O\PSKRLG RUJDQV  These 




MS activity independently of its immunological functions.9 8 5 This review addresses these 
HIIHFWV ZLWK UHJDUG WR WKH LQWHUDFWLRQV RI )7< DQG 63 ZLWK 63 UHFHSWRUV IRXQG RQ




 Studies like this have primarily focused on S1P1 DV WKH NH\PHGLDWRU RI 63 DQG)7<
effects. Some reports have shown that S1P1 LV UHVSRQVLEOH IRU  RI 63 UHFHSWRU
activity, depending on the region of the brain assessed. Some studies have suggested that 
)7<3LVDSRWHQWDJRQLVWRI631 but only a partial agonist of S1P, ZKLOHRWKHUV·ÀQGLQJV




and inhibited by S1P1-selective antagonists.Taken together, research seems to indicate that 
WKHHIÀFDF\RIÀQJROLPRG LVDFKLHYHGSULPDULO\ WKURXJK631, but it is reasonable to expect 
that its interactions with other S1P receptors also contribute to its observed effects. This review 
addresses the potential contributions of both astrocytic S1P1 and S1PLQWHUDFWLRQVLQWKHHIÀFDF\
RIÀQJROLPRGDQGWKHPROHFXODUSDWKRORJ\RI06ZLWKWKHXQGHUVWDQGLQJWKDW631-mediated 
effects are likely dominant.
These S1P receptors were selected for analysis because S1P1 and S1P are the most abundant 
S1P receptors on astrocytes.7KHH[SUHVVLRQRIERWK UHFHSWRUV LV VLJQLÀFDQWO\ LQFUHDVHG
in reactive astrocytes, and both receptors are found in active MS lesions. Furthermore, 
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both receptors contribute to the development of reactive astrogliosis. S1P has been found to 
induce astrogliosis both in vitro and in vivo via the S1P1 and S1P pathways,DQG)7<
exposure or deletion of S1P1 or S1P has been shown to inhibit astrogliosis.As previously 
GHVFULEHGDVWURJOLRVLVFRQWULEXWHVWRWKHSDWKRORJ\RI06E\SURORQJLQJWKH&16LQÁDPPDWRU\
reaction in MS lesions and preventing remyelination.17 16 Fingolimod treatment has been shown 
to moderate astrogliosis.5
7KHPHFKDQLVPRIDFWLRQRIÀQJROLPRGLVOLNHO\WREHVLPLODULQ631 and S1P receptors. There 
is a high degree of structural homology among S1P receptors, particularly with regard to their 
ligand binding pocket and residues associated with the activating conformational change of the 
receptor. The surface expression of both receptors is dependent on similar phosphorylation 
patterns, suggesting that the alterations in phosphorylation that affect internalization and 
subsequent degradation of S1P1DIWHU)7<3ELQGLQJZLOOVLPLODUO\DIIHFW63. Additionally, 
physiological effects associated with S1P activation have been observed at the initiation of 
WUHDWPHQWZLWK ÀQJROLPRG but they are only transient,8 suggesting activation followed by 
IXQFWLRQDODQWDJRQLVPLQWKHVDPHPDQQHUDVVRFLDWHGZLWKÀQJROLPRGDFWLYLW\DW631.
Astrocytic S1P receptors function in regulating permeability of the blood-
brain barrier
Studies have shown that the integrity of the blood-brain barrier is compromised at the sites 
of active multiple sclerosis lesions. Enhanced permeability of the BBB facilitates increased 
WUDQVHQGRWKHOLDO PLJUDWLRQ RI DFWLYDWHG LPPXQH V\VWHP FHOOV LQFUHDVLQJ WKH LQÁDPPDWRU\
UHVSRQVHDQGGHP\HOLQDWLRQLQWKH&167UHDWPHQWZLWKÀQJROLPRGKDVEHHQVKRZQWRUHGXFH
this breakdown of the BBB. 
Regulation of the BBB phenotype is a cooperative effort involving bidirectional crosstalk 
between cerebral endothelial cells and astrocytes. CECs make up the walls of blood 
vessels and form the primary barrier separating materials in the blood from the CNS. Astrocytes 
IRUPDVHFRQGDU\EDUULHUFRPSRQHQW7KHVHFHOOVFRYHURIWKHVXUIDFHDUHDRI&(&VDQG
serve as key regulators of their function. Communication between the two cells types is essential 
for BBB integrity.
7KHFRPELQHGSHUWLQHQFHRIDVWURF\WHVLQPDLQWDLQLQJWKH%%%DQGWKHHIÀFDF\RIÀQJROLPRGLQ
reducing MS effects on its integrity demonstrate a role for astrocytic S1P receptors in regulating 
the permeability of the BBB. Indeed, activity of the S1P1 and S1P receptors has been shown 
to modulate BBB integrity directly by affecting astrocytic gap junctions.Gap junctions on 
astrocytes are essential for communication among groups of astrocytes and among astrocytes 
and their neighboring cells, including CECs. Heightened S1P1 and S1P activity associated 
ZLWK UHDFWLYH DVWURJOLRVLV VLJQLÀFDQWO\ LQKLELWV WKH IRUPDWLRQ DQG IXQFWLRQ RI WKHVH JDS
junctions. This impairs astrocyte communication with the CECs and severely compromises 
the BBB.7KLVJHQHUDOZHDNHQLQJRIWKH%%%ZRXOGSHUPLWVLJQLÀFDQWO\PSKRF\WHPLJUDWLRQ
into the CNS. It has been established that frequent penetration by invading cells can cause 
lasting damage to the affected blood vessels, causing the BBB disruption proximal to MS 
OHVLRQVDQGFRQWULEXWLQJSHUKDSV WR WKHFKURQLFFHUHEURVSLQDOYHQRXV LQVXIÀFLHQF\ WKDWKDV
been documented in some MS patients. Functional antagonism of S1P1 and S1P receptors 
E\ÀQJROLPRGZRXOG UHVWRUHDVWURF\WHFRPPXQLFDWLRQZLWK&(&V UHVXOWLQJ LQ WKHREVHUYHG
improvements in BBB phenotype and contributing to the reduction of MS symptoms associated 
ZLWKÀQJROLPRGWUHDWPHQW
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S1P receptors mediate inflammatory cytokine and chemokine secretion
When CNS damage occurs or the BBB is penetrated, astrocytes are activated and begin to 
VHFUHWHSURLQÁDPPDWRU\7KF\WRNLQHV Some of these cytokines including interferon gamma 
,)1JWXPRUQHFURVLVIDFWRUDOSKD71)ƠDQGLQWHUOHXNLQV,/ơDQGKDYHEHHQ
directly associated with MS pathology. The production of many of these cytokines has 
EHHQDWWULEXWHGWR63UHFHSWRUVLJQDOLQJ([SUHVVLRQRI,)1Ƣ,/ơ,/DQG,/KDVEHHQ
VLJQLÀFDQWO\UHGXFHGE\ERWKÀQJROLPRGWUHDWPHQWDQGFRQGLWLRQDOGHOHWLRQRIDVWURF\WLF631.9 
/HVVLVNQRZQDERXWWKHVSHFLÀFHIIHFWVRI63 on cytokine production, but its activity has 
EHHQFRUUHODWHGZLWKLQFUHDVHGSURGXFWLRQRIVHYHUDOLQÁDPPDWRU\F\WRNLQHVDQGFKHPRNLQHV
among them several that have been implicated in MS pathology. Additionally, the presence 
RI71)ƠKDVEHHQVKRZQWRVXEVWDQWLDOO\LQFUHDVHWKHH[SUHVVLRQRI63 and to moderately 
increase the expression of S1P1 on astrocytes, indicating a role for the receptors in this cytokine 
signaling pathway. It has been proposed that S1P signaling in particular stimulates the pro-
LQÁDPPDWRU\HIIHFWVRI71)ƠDQGWKDWWKHF\WRNLQHDFWVDVDV\QHUJLVWRQ63, enhancing the 
vascular disruption and other effects associated with S1P signaling.11 
$VWURF\WH SURGXFWLRQ RI SURLQÁDPPDWRU\ F\WRNLQHV KHOSV WR LQLWLDWH DQG VXVWDLQ WKH &16
LQÁDPPDWRU\ UHVSRQVH LQ PXOWLSOH VFOHURVLV   Th1 cytokines are the initial stimuli that 
activate astrocytes and microglia, causing them to become immunoreactive and proliferate.
 Astrocytic cytokine production induces the expression of adhesion molecules such as 
ICAM-1, ECAM-1, PECAM-1, and E-selectin on CECs that guide activated lymphocytes to 




chemokines direct lymphocyte movement and adhesion to the BBB. They also facilitate the 
transition from selectin-mediated adhesion to integrin-mediated interactions that enable 
lymphocytes to cross the BBB. Unsurprisingly, a number of chemokines have been associated 
with MS activity.  The expressions of several of these appear to be dependent on S1P 
UHFHSWRUVLJQDOLQJ&&/DFKHPRNLQHWKDWFRQWULEXWHVWRGHP\HOLQDWLRQLQPXOWLSOHVFOHURVLV
LVLQKLELWHGE\ÀQJROLPRGPDNLQJLQWHUDFWLRQZLWK631 and/or S1P receptors probable. Both 
S1P1 and S1PKDYHEHHQGHÀQLWLYHO\LPSOLFDWHGLQWULJJHULQJWKHSURGXFWLRQRIWKHFKHPRNLQH
MCP-1. The expression of MCP-1 has also been shown to decrease following treatment with 
ÀQJROLPRG Functional antagonism of astrocytic S1P1 and S1P receptors prevents the receptors 
IURP LQGXFLQJ SURLQÁDPPDWRU\ F\WRNLQH SURGXFWLRQ OHVVHQLQJ WKH DVWURF\WLF LQÁDPPDWRU\
response and inhibiting further proliferation of reactive astrocytes.
The interactions of S1P receptor signaling, cytokine and chemokine production, and CNS 
LQÁDPPDWLRQDUHFRPSOH[,QDGGLWLRQWRLQKLELWLQJWKHSURGXFWLRQRIQXPHURXVSURLQÁDPPDWRU\
cytokines, functional antagonism of S1P1 would also decrease the production of some anti-
LQÁDPPDWRU\F\WRNLQHVVXFKDV,1)ơDQGFKHPRNLQHVVXFKDV&;&/631 also inhibits 
VRPHFRPSRQHQWVRI71)ƠPHGLDWHGVLJQDOLQJDQGLWVLQDFWLYDWLRQZRXOGUHVXOWLQWKHORVV
RIDQHJDWLYHUHJXODWRURISURLQÁDPPDWRU\VLJQDOLQJ,WLVSRVVLEOHWKDWÀQJROLPRGPD\KDYH
different effects on S1P receptors in different tissue types, particularly in CECs, that contribute 
WRLWVHIÀFDF\LQVSLWHRIWKHVHFRPSOLFDWLRQV,WKDVDOVREHHQVXJJHVWHGWKDWÀQJROLPRGWUHDWPHQW
in fact facilitates a transition in cytokine production from the Th1 type immune response to a 
7KW\SHLQZKLFKPRUHDQWLLQÁDPPDWRU\PROHFXOHVDUHVHFUHWHG While this hypothesis 
requires further substantiation, it can be reasonably concluded at this time that inhibition of S1P1 
and S1PUHFHSWRUVFRQWULEXWHWRDQRYHUDOOUHGXFWLRQLQWKHDVWURF\WLFLQÁDPPDWRU\UHVSRQVH
that is associated with cytokine and chemokine production.
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Positive feedback between S1P receptor and growth factor receptor 
signaling pathways contribute to MS pathology
S1P, the natural ligand of S1P receptors, is formed by the phosphorylation of sphingosine 
PROHFXOHV E\ VSKLQJRVLQH NLQDVH  6SK. *URZWK IDFWRU UHFHSWRU VLJQDOLQJ LQFUHDVHV
WKH SURGXFWLRQ RI 63 E\ DFWLYDWLQJ 6SK. &RQVHTXHQWO\ DQ LQFUHDVH LQ JURZWK IDFWRU
concentration often results in the transactivation of astrocytic S1P receptors. S1P receptor 
signaling frequently stimulates the production of growth factors by astrocytes, creating a series 
of positive feedback loops that result from crosstalk between growth factor (GF) and S1P 
signaling pathways.7KHDPSOLÀFDWLRQRIERWKVLJQDOLQJSDWKZD\VFDQLQFUHDVHGLVHDVH
activity associated with multiple sclerosis. 




molecules17 and enhances vascular permeability.7KLVKHOSVWRSURORQJWKH&16LQÁDPPDWRU\
response and to increase its severity by permitting additional lymphocytes to cross the BBB. The 
high levels of S1P that can result from S1P-GF positive feedback loops can also contribute to 
CNS damage independent of a signaling pathway.  While S1P normally promotes cell survival, 
prolonged exposure to high levels of S1P has been shown to trigger cell apoptosis. Treatment 
ZLWKÀQJROLPRGFDQUHGXFHWKHVHDGYHUVHHIIHFWV7KHGUXJKDVSURYHQHIIHFWLYHLQLQKLELWLQJ
WKHELRV\QWKHVLVRI63DQG63SUHFXUVRUVLQFOXGLQJ6SK.
Growth factors can also have individual effects on the CNS that contribute to the pathology of 
MS. Excessive production of vascular endothelial growth factor (VEGF) is typically observed 
in MS. Increased concentrations of this growth factor alter intercellular junctions and increase 
BBB permeability and at the same time promote lymphocyte migration. VEGF also triggers 
WKHSUROLIHUDWLRQRI UHDFWLYH DVWURF\WHV FRQWULEXWLQJ WR WKHPDQ\SURLQÁDPPDWRU\ HIIHFWV RI
astrogliosis.16 6LJQLÀFDQW FURVVWDON RFFXUV EHWZHHQ WKH 9(*) DQG 631 pathways. S1P1 
activity stimulates astrocytic secretion of VEGF, and VEGF increases the expression of S1P1. 
The desensitization of S1P1IROORZLQJÀQJROLPRGWUHDWPHQWKDVEHHQVKRZQWRSURWHFWDJDLQVW
vascular permeability induced by VEGF, and the removal of this essential component of the 
feedback loop likely contributes to the reduction in astrogliosis associated with the drug.5 The 
same feedback loop mechanism exists between S1P1DQGWKHÀEUREODVWJURZWKIDFWRU)*) 
FGF also stimulates reactive astrocyte proliferation,16DQGWKLVDFWLYLW\LVEORFNHGE\ÀQJROLPRG·V
inhibition of S1P1DQG6SK.
Both S1P1 and S1P receptors on astrocytes have been found to increase signaling by epidermal 
growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR),50 and platelet-
derived growth factor receptor (PDGFR). Astrocytes produce EGFR in response to neural 
injury like that caused by multiple sclerosis. This growth factor stimulates astrocytes to release 
SURLQÁDPPDWRU\VXEVWDQFHVVXFKDV63DWWKHVLWHRILQMXU\LQDQHIIRUWWRFRQÀQHDQGHOLPLQDWH
the antigen source.51 IGF-1 is produced primarily by astrocytes. It stimulates the cells’ 
proliferation and survival,50 and it has been associated with demyelination in MS and related 
diseases. Both EGFR and IGFR are unusually active in MS lesions, and this potentiation of 
their signaling has been causally linked to the activity of the S1P1 and S1P receptors.50 This 
provides strong evidence for the integral role of reactive astrocytes and their S1P receptors in 
MS pathology. PDGFR activity is associated with cell migration, and it has also been linked 
WRUHDFWLYHDVWURF\WHSUROLIHUDWLRQDQGWRDVWURF\WLFVHFUHWLRQRI,/ơDQG0&3 PDGFR 
signaling contributes to the most critical features of reactive astrogliosis, and its activity as well 
as certain aspects of S1P signaling are mutually dependent on positive feedback between the two 
pathways.  By desensitizing S1P1 and S1PUHFHSWRUVLQKLELWLQJWKHDFWLYLW\RI6SK.DQG
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WKHELRV\QWKHVLVRI63DQGOLPLWLQJWKHSUROLIHUDWLRQRIUHDFWLYHDVWURF\WHVÀQJROLPRGZLOO
VLJQLÀFDQWO\UHGXFHWKHH[SUHVVLRQRIJURZWKIDFWRUVWKDWLQWHUDFWZLWKWKH63SDWKZD\
Conclusions: Role of Astrocytic S1P Receptors in MS Pathology
Reactive astrogliosis has long been recognized as a feature of multiple sclerosis. In a typical 
response to nerve damage, reactive astrocytes proliferate around the locations at which myelin-
reactive lymphocytes have crossed the BBB and begun degrading myelin sheaths. Reactive 
DVWURF\WHVWKHQFRQWULEXWHWRWKHLQÁDPPDWRU\UHVSRQVHE\SURGXFLQJKLJKFRQFHQWUDWLRQVRI
63LQDGGLWLRQWRSURLQÁDPPDWRU\F\WRNLQHVFKHPRNLQHVDQGJURZWKIDFWRUV Signaling 
through the astrocytic S1P1 and S1P pathways is essential for the initiation and potentiation of 
DOORIWKHNH\IHDWXUHVRIWKLVLQÁDPPDWRU\UHVSRQVHLQFOXGLQJWKHZHDNHQLQJRIWKH%%%DV
well as for the proliferation, migration, and survival of the reactive astrocytes. This response 
can be adaptive in many cases of CNS injury, but in an autoimmune disorder such as MS in 
which the target antigen is a normal and abundant component of the CNS, the antigen source 
FDQQRWEHHDVLO\FRQÀQHGDQGHOLPLQDWHG7KXVWKHQRUPDOIXQFWLRQRIUHDFWLYHDVWURF\WHVDQG
particularly of the S1P1 and S1P receptors likely serves to aggravate and prolong the initial MS 
autoimmune response, contributing to the progressive demyelination and neurodegeneration 
associated with the disease. 
Increasingly, however, research is beginning to suggest a more direct role for S1P receptors in 
the pathology of MS. Both S1P1 and S1P are expressed at abnormally high levels in MS lesions, 
and the expression of S1P1 has been directly correlated with the degree of demyelination. 
The conditional deletion of astrocytic S1P1 reduced levels of demyelination and lessened the 
severity of all symptoms associated with EAE.90RVWVLJQLÀFDQWO\WUHDWPHQWZLWKÀQJROLPRG
prior to challenge with myelin antigens has been shown repeatedly to prevent the development 
of EAE.8 In conjunction with the data identifying astrocytic S1P1 as the primary mediator of 
ÀQJROLPRG·VWKHUDSHXWLFHIIHFWV9WKHVHÀQGLQJVLQGLFDWHWKDWWKHDFWLYLW\RIDVWURF\WLF631 is an 
essential component in the pathogenesis of EAE. 
While astrocytic S1P1 may mediate the primary CNS activity in demyelinating disorders, 
lymphocytic S1P1 may contribute to another aspect of the autoimmune reaction. A recent study 
discovered that this receptor was responsible for regulating T-cell differentiation. S1P1 signaling 
VWLPXODWHVWKHGHYHORSPHQWRI&'7+FHOOV²WKHUHDFWLYH7FHOOVDVVRFLDWHGZLWKWKHLQLWLDO
DXWRLPPXQHUHDFWLRQWRP\HOLQ²DQGLQKLELWVWKHIRUPDWLRQRIUHJXODWRU\&'&')R[3
T-cells.+\SHUDFWLYHVLJQDOLQJRUVLJQLÀFDQWO\LQFUHDVHGH[SUHVVLRQRI631 could thus explain 
WKHGHÀFLHQF\LQUHJXODWRU\7FHOOVREVHUYHGLQLQGLYLGXDOVZLWK06$V\VWHPDWLFLQFUHDVHLQ
S1P receptor activity would also help to explain the unusually high levels of S1P and growth 
IDFWRUV SUHVHQW LQ WKH FHUHEURVSLQDO ÁXLG RI06 SDWLHQWV17 This abnormal receptor activity 
would serve as the initial stimulus for the potentiation of the S1P-GF feedback loop systems. 
Further research is needed to determine the precise roles of the S1P1 and S1P receptors in 
WKHPHFKDQLVP RI DFWLRQ RI ÀQJROLPRG DQG LQ WKH SDWKRORJ\ DQG SDWKRJHQHVLV RI PXOWLSOH
sclerosis. It is apparent, however, that this novel MS drug achieves its therapeutic effects 
by regulating signaling pathways that are critical components in the function of the immune 
system. A growing body of research is generating information implicating S1P1 and other S1P 
receptors in the pathology of other diseases including systematic lupus erythematosus (SLE), 
myocarditis, type-I diabetes, arthritis, colitis, atherosclerosis,SIV encephalitis, and even 
cancer. It seems likely that the S1P receptors will soon be recognized as key elements of 
WKHERG\·VLQÁDPPDWRU\DQGLPPXQHUHVSRQVHV7KH\PD\DOVREHFRPHNH\WDUJHWVIRUGUXJ
design, especially since the crystal structure of S1P1 has now been obtained, with structures 
of the other S1P receptors likely to follow.55 The new structural data will enable scientists to 
LGHQWLI\WKHSUHFLVHLQWHUDFWLRQVRI)7<3LQWKHELQGLQJSRFNHWRI631 and the other S1P 
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receptors and to settle the remaining debates regarding the drug’s mechanism of action. The 
growing understanding of the S1P receptors may provide new insight into the pathology of 
multiple sclerosis and perhaps other autoimmune disorders as well as the opportunity to develop 
PRUHVSHFLÀFDQGPRUHHIIHFWLYHGUXJVWRWUHDWWKHP
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mechanism similar to tricyclic antidepressants. Biochemical and biophysical research 
FRPPXQLFDWLRQV
 'DQLHO&6DUWRU\1=DKQ1*HLVVOLQJHU*5DGHNH++6WHLQ-0)7<














 Multiple Sclerosis Mechanisms 39 























 Brinkmann, V., Sphingosine 1-phosphate receptors in health and disease: mechanistic 
insights from gene deletion studies and reverse pharmacology. Pharmacology & 
WKHUDSHXWLFV
 .LP+-0LURQ9('XNDOD'3URLD5//XGZLQ6.7UDND0$QWHO-3














between sphingosine-1-phosphate and vascular endothelial growth factor signalling in 
0/IROOLFXODUWK\URLGFDUFLQRPDFHOOV(QGRFULQHUHODWHGFDQFHU
 ,JDUDVKL-(UZLQ3$'DQWDV$3&KHQ+0LFKHO79(*)LQGXFHV63UHFHSWRUV
in endothelial cells: Implications for cross-talk between sphingolipid and growth factor 
















Tat-mediated induction of platelet-derived growth factor in astrocytes: role of early 
JURZWKUHVSRQVHJHQH-,PPXQRO
 %DXGKXLQ/0-LDQJ<=DVODYVN\$,VKLL,&KXQ-;X<63PHGLDWHG
Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). 
7KH)$6(%MRXUQDORIÀFLDOSXEOLFDWLRQRIWKH)HGHUDWLRQRI$PHULFDQ6RFLHWLHVIRU
([SHULPHQWDO%LRORJ\
 /LX*<DQJ.%XUQV66KUHVWKD6&KL+7KH63P725D[LVGLUHFWVWKH
UHFLSURFDOGLIIHUHQWLDWLRQRI7+DQG7UHJFHOOV1DWXUHLPPXQRORJ\

55. +DQVRQ0$5RWK&%-R(*ULIÀWK076FRWW)/5HLQKDUW*'HVDOH+
&OHPRQV%&DKDODQ606FKXHUHU6&6DQQD0*+DQ*:.XKQ3
5RVHQ+6WHYHQV5&&U\VWDO6WUXFWXUHRID/LSLG*3URWHLQ&RXSOHG5HFHSWRU
6FLHQFH
